Akut limfoid leukémia (ALL): vizsgálatok itt: Kína
169 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleCD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Where
- Beijing
- Életkor
- 14 év to 75 év
- People
- 12
- Run by
- Liping Dou
See details and how to joinNCT07927816 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Xian, Zhengzhou
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - No phaseNot yet taking people in KínaBusulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- Where
- Beijing
- Életkor
- 14 év to 65 év
- People
- 180
- Run by
- Peking University People's Hospital
See details and how to joinNCT07919470 - 1. fázisTaking peopleIn VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
- Where
- Kunming
- Életkor
- 18 év and over
- People
- 24
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07239323 - 1/2. fázisNot yet taking people in KínaCAR-T Immunotherapy Targeting CD19- ALL
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 100
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129 - 1/2. fázisNot yet taking people in KínaMulti-CAR T Cell Therapy Targeting CD7-positive Malignancies
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302 - 1. fázisNot yet taking people in KínaUniversal 4SCAR7U Targeting CD7-positive Malignancies
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995028 - 1. fázisTaking peopleGN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
- Where
- Kunming, Pu'er
- Életkor
- 18 év to 75 év
- People
- 42
- Run by
- Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
See details and how to joinNCT07910708 - 1/2. fázisTaking peopleA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Where
- Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Shijiazhuang, Tianjin, Wuhan, Xuzhou, Zhengzhou
- Életkor
- 2 év and over
- People
- 203
- Run by
- MSD R&D (China) Co., Ltd.
See details and how to joinNCT05579132 - 1. fázisTaking peoplePhase Ib Clinical Study of Keynatinib
- Where
- Beijing, Chengdu, Shanghai
- Életkor
- 18 év and over
- People
- 75
- Run by
- Medolution Ltd.
See details and how to joinNCT04807881 - No phaseTaking peopleUsing Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
- Where
- Tianjin
- Életkor
- Up to 16 év
- People
- 100
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07278882 - 2. fázisTaking peopleVenetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
- Where
- Suzhou
- Életkor
- 14 év to 75 év
- People
- 27
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07159620 - 1/2. fázisTaking peopleStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Where
- Guangzhou, Tianjin
- Életkor
- 12 év and over
- People
- 83 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00 - 1. fázisTaking peoplePhase I Study of FXS0683 in the Treatment of Blood Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 228
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089 - 1/2. fázisTaking peopleAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Where
- Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
- Életkor
- 12 év and over
- People
- 255 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00 - Korai 1. fázisTaking peopleStudy of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
- Where
- Yunnan
- Életkor
- 18 év to 75 év
- People
- 18
- Run by
- Hematology department of the 920th hospital
See details and how to joinNCT07862010 - 1. fázisTaking peopleBEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Where
- Suzhou
- Életkor
- 14 év to 75 év
- People
- 15
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07854652 - 1. fázisTaking peopleDual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 18
- Run by
- Ruijin Hospital
See details and how to joinNCT07838714 - 2. fázisNot yet taking people in KínaImmunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 22
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07840976 - Korai 1. fázisNot yet taking people in KínaSNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Where
- Changchun
- Életkor
- 18 év to 75 év
- People
- 28
- Run by
- Shanghai Simnova Biotechnology Co.,Ltd.
See details and how to joinNCT07830238 - 2. fázisTaking peopleA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Where
- Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Henan, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan
- Életkor
- 3 év to 21 év
- People
- 100
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT05334823 - No phaseTaking peoplePh+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
- Where
- Hangzhou
- Életkor
- 1 hónap to 18 év
- People
- 500
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07813208 - No phaseTaking peopleBlinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 114
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07003737 - 1. fázisTaking peopleU69-CART-Cells For R/R T-ALL
- Where
- Suzhou
- Életkor
- 15 év to 75 év
- People
- 12
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07350863 - 1. fázisTaking peopleStudy for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
- Where
- Hefei, Jinan, Shanghai, Tianjin
- Életkor
- 1 év to 18 év
- People
- 19
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05495035